The currently most widely used biomarker is PD-L1 expression in the tumor, as assessed by the PD-L1 tumor proportion score (TPS), which is positively associated with a response to ICI treatment in metastatic NSCLC patients [4]. This evidence concerns the gene CD274 and neoplasm.